ValuEngine cut shares of Affimed (NASDAQ:AFMD) from a buy rating to a hold rating in a report issued on Tuesday morning.

A number of other research analysts have also commented on the company. Jefferies Financial Group upgraded Affimed from a hold rating to a buy rating and upped their target price for the company from $1.80 to $4.00 in a research note on Tuesday, August 28th. BidaskClub upgraded Affimed from a strong sell rating to a sell rating in a research note on Friday, August 31st. BMO Capital Markets cut their target price on Affimed from $6.00 to $4.00 and set an outperform rating for the company in a research note on Thursday, August 9th. Finally, Zacks Investment Research upgraded Affimed from a hold rating to a buy rating and set a $5.25 target price for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Affimed currently has a consensus rating of Hold and an average price target of $4.81.

Shares of AFMD stock opened at $3.38 on Tuesday. Affimed has a 12 month low of $1.15 and a 12 month high of $7.35. The company has a market cap of $271.40 million, a PE ratio of -4.33 and a beta of 3.57. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.36 and a quick ratio of 5.33.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Affimed had a negative return on equity of 74.04% and a negative net margin of 1,723.04%. The company had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.61 million. Equities analysts anticipate that Affimed will post -0.63 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of AFMD. Stanley Laman Group Ltd. acquired a new position in shares of Affimed in the second quarter valued at $100,000. Barclays PLC raised its stake in shares of Affimed by 385.3% in the first quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 51,573 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Affimed in the second quarter valued at $165,000. Sofinnova Ventures Inc acquired a new position in shares of Affimed in the first quarter valued at $205,000. Finally, Renaissance Technologies LLC raised its stake in shares of Affimed by 38.8% in the second quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 49,610 shares in the last quarter. Institutional investors and hedge funds own 40.63% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.